menu
    • menu

    Company profile for Apnimed

    NEW Drugs in Dev: 13
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Apnimed was founded in 2017 and is located in Cambridge, MA. We are a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ApnimedUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    20 Holyoke Street, Cambridge, MA 02138
    Telephone
    Telephone
    (617) 500-8880
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://apnimed.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ApniMed Secures Up to $150M Debt from HealthCare Royalty Partners
    ApniMed Secures Up to $150M Debt from HealthCare Royalty Partners

    06 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apnimed-secures-up-to-150-million-in-debt-financing-with-healthcare-royalty-partners-to-support-planned-ad109-commercial-launch-302734406.html

    PR NEWSWIRE
    06 Apr 2026
    Share Share
    ApniMed Monetizes SASS Stake for $150M + AD109 Royalties
    ApniMed Monetizes SASS Stake for $150M + AD109 Royalties

    24 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apnimed-announces-strategic-monetization-of-shionogi-apnimed-sleep-science-sass-joint-venture-stake-for-150m-and-royalties-strengthening-focus-on-its-wholly-owned-osa-program-ad109-302722702.html

    PR NEWSWIRE
    24 Mar 2026
    Share Share
    Apnimed To Join Lifesci Capital & Sofinnova Partners Summit
    Apnimed To Join Lifesci Capital & Sofinnova Partners Summit

    10 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apnimed-to-participate-in-the-lifesci-capital--sofinnova-partners-growth-and-innovation-summit-302607744.html

    PR NEWSWIRE
    10 Nov 2025
    Share Share
    Apnimed Publishes Positive Phase 2 Results of OSA in Lancet
    Apnimed Publishes Positive Phase 2 Results of OSA in Lancet

    03 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apnimed-announces-publication-in-the-lancet-of-positive-phase-2-results-demonstrating-sulthiames-efficacy-in-obstructive-sleep-apnea-302602583.html

    PR NEWSWIRE
    03 Nov 2025
    Share Share
    Apnimed To Present Phase 3 Data For AD109, At CHEST 2025 Meeting
    Apnimed To Present Phase 3 Data For AD109, At CHEST 2025 Meeting

    17 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apnimed-to-present-additional-phase-3-data-for-ad109-an-investigational-oral-pill-for-obstructive-sleep-apnea-at-chest-2025-annual-meeting-302587042.html

    PR NEWSWIRE
    17 Oct 2025
    Share Share
    Apnimed Presents Positive AD109 Phase 3 Data At CHEST Meeting
    Apnimed Presents Positive AD109 Phase 3 Data At CHEST Meeting

    07 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apnimed-announces-acceptance-of-two-late-breaking-presentations-and-a-core-interactive-session-at-the-chest-annual-meeting-highlighting-new-positive-ad109-phase-3-data-and-the-current-unmet-need-in-obstructive-sleep-apnea-302576420.html

    PR NEWSWIRE
    07 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search